Cynthia Knight, APRN
Nurse Practitioner · Seaford, DENPI 1134199029
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 188 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 17.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $911, 2.2 times the $418 reported in 2021. Among nurse practitioner clinicians in DE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 188 payments — averaging $20.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$649
- Abbott$470
- Lilly USA, LLC$283
- AbbVie$277
- AstraZeneca$198
- Jazz Pharmaceuticals Inc.$169
- plus $2K from 32 others
What the payments were for
- Food & beverage$3,795100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 35 | $649 |
| Abbott | 28 | $470 |
| Lilly USA, LLC | 15 | $283 |
| AbbVie | 13 | $277 |
| AstraZeneca(2 entities) | 7 | $198 |
| Jazz Pharmaceuticals Inc. | 9 | $169 |
| Mallinckrodt Hospital Products Inc. | 5 | $156 |
| Dexcom, Inc. | 6 | $110 |
| Medline Industries LP | 1 | $110 |
| Pfizer | 6 | $106 |
| GSK | 5 | $104 |
| Amgen | 6 | $103 |
| Merck | 4 | $102 |
| UCB, Inc. | 4 | $100 |
| Lundbeck LLC | 3 | $84 |
| Xeris Pharmaceuticals, Inc. | 4 | $67 |
| Boehringer Ingelheim | 3 | $67 |
| Exact Sciences | 3 | $63 |
| Sanofi | 2 | $56 |
| Insulet Corporation | 3 | $56 |
| Phathom Pharmaceuticals, Inc. | 4 | $54 |
| Eisai Inc. | 3 | $46 |
| Astellas Pharma US Inc | 2 | $42 |
| Sanofi-aventis U.S. LLC | 2 | $34 |
| BETA Bionics, Inc. | 2 | $33 |
| Radius Health, Inc. | 1 | $25 |
| W. L. Gore & Associates, Inc. | 1 | $24 |
| Bayer | 1 | $22 |
| Biohaven Pharmaceuticals, Inc. | 1 | $21 |
| Boston Scientific | 1 | $20 |
| Corcept Therapeutics | 1 | $20 |
| Medtronic | 1 | $20 |
| SK Life Science, Inc. | 1 | $20 |
| Tandem Diabetes Care, Inc. | 1 | $18 |
| ANI Pharmaceuticals, Inc. | 1 | $18 |
| Neurelis, Inc. | 1 | $17 |
| Grifols USA, LLC | 1 | $16 |
| Biogen | 1 | $16 |
How this compares
$3,795 in reported general payments places this provider in the 90th percentile of 487 nurse practitioner providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 107 | $93,529 |
| JardianceEmpagliflozin | 48 | $46,758 |
| FarxigaDapagliflozin Propanediol | 29 | $37,894 |
| XifaxanRifaximin | 16 | $37,301 |
| RybelsusSemaglutide | 41 | $36,472 |
| OzempicSemaglutide | 25 | $34,334 |
| XareltoRivaroxaban | 36 | $30,558 |
| MyrbetriqMirabegron | 43 | $23,538 |
| MounjaroTirzepatide | 21 | $21,871 |
| JanuviaSitagliptin Phosphate | 21 | $20,296 |
| ByettaExenatide | 20 | $18,191 |
| Victoza 3-PakLiraglutide | 12 | $14,527 |
| EntrestoSacubitril/Valsartan | 15 | $11,766 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 18 | $8,986 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 14 | $7,649 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Paxlovid | $106 | $96,388132 claims |
| Novo NordiskRybelsus, Ozempic | $649 | $70,80666 claims |
| AstraZenecaFarxiga, Byetta | $198 | $56,08549 claims |
| Boehringer IngelheimJardiance | $67 | $46,75848 claims |
| Astellas Pharma US IncMyrbetriq | $42 | $23,53843 claims |
| Lilly USA, LLCMounjaro | $283 | $21,87121 claims |
| MerckJanuvia | $102 | $20,29621 claims |
| GSKAnoro Ellipta, Breo Ellipta, Arnuity Ellipta | $104 | $18,90151 claims |
| AbbVieSynthroid | $277 | $2,99754 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 487 nurse practitioner providers in Delaware.
Other nurse practitioner in Seaford
- Meghan McCarterSeaford$170K
- Gayle WhaleySeaford$6K
- Sherry GardinerSeaford$6K
- Melissa KestlerSeaford$5K
- Peter LerzaSeaford$2K
- Chandni PatelMiddletown$113K
- Craig LaingMilford$51K
- Colleen DitroWilmington$16K
- Sedelle Henderson-BamideleNewark$13K
- Jennifer HubbardWilmington$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.